Hopp til innhold
NHI.no
Annonse

Trombotisk trombocytopenisk purpura: Symptomer ved TTP

Innhold i artikkelen

De vanligste symptomene tidlig i sykdommen er uspesifikke og inkluderer magesmerter, kvalme, brekninger og en følelse av svakhet. Siden mange ulike organer kan skades av små blodpropper, gir sykdommen derfor ulike symptomer.

Annonse

Omtrent halvparten har tegn på skader i sentralnervesystemet enten ved starten av sykdommen eller i forløpet. Symptomene kan være hodepine, forvirring, tap av evne til å snakke, bevissthetsendringer fra lett sløvhet til koma. Typisk er at symptomene kan variere over minutter. Noen har lite uttalte symptomer med kun forbigående forvirring. Ved mer fremskreden sykdom kan det observeres lammelser og kramper.

Andre tegn på sykdommen kan være hudblødninger, svakhet som følge av lav blodprosent, nyresvikt eller svikt i andre organer. Feber er uvanlig. Selv om sykdommen oftest har en akutt start, vil en fjerdedel av pasientene ha hatt symptomer i flere uker før diagnosen stilles.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Trombotisk trombocytopenisk purpura . Referanselisten for dette dokumentet vises nedenfor

  1. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-35. New England Journal of Medicine
  2. von Krogh AS, Waage A, Quist-Paulsen P. Kongenital trombotisk trombocytopenisk purpura. Tidsskriftet 2016; 136: 1452-7. tidsskriftet.no
  3. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood 2017; 129: 2836-46. pmid:28416507 PubMed
  4. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-86. PubMed
  5. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-35. pmid:22624596 PubMed
  6. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003; 10: 339-44. PubMed
  7. Veyradier A, Meyer D. Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost 2005; 3: 2420-7. PubMed
  8. Bohm M, Betz C, Miesbach W, et al. The course of ADAMTS13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 2005; 129: 644-52. PubMed
  9. Burns ER, Lou Y, Pathak A. Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am J Hematol 2004; 75: 18-21. PubMed
  10. Gøtze JP, Hillarp A, Lindblom A, Björk P, Strandberg K, Nielsen LB. Ny markør ved trombotisk trombocytopenisk purpura. Ugeskr Læger 2008; 170: 2446. PubMed
  11. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600. New England Journal of Medicine
  12. George JN, Cuker A. Acquired TTP: Initial treatment. UpToDate, last updated Sep 30, 2020. UpToDate
  13. Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD003595. DOI: 10.1002/14651858.CD003595.pub2 DOI
  14. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 2019; 380: 335-46. pmid:30625070 PubMed
  15. Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med 2014;5:15-23 PubMed
  16. Scully, M., Cohen, H., Cavenagh, J. et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Haematol 2007; 136: 451-61. pmid:17233847 PubMed
  17. Froissart A, Veyradier A, Hié M et al.. Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story. Eur J Intern Med 2015; 26: 659-65. pmid:26293834 PubMed
  18. Peyvandi F, Scully M, Hovinga JAK, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016; 374:511-22. doi: 10.1056/NEJMoa1505533 DOI
  19. FDA News release. FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder. Publisert februar 2019. www.fda.gov
  20. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-86. PubMed
  21. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003; 290: 1360-70. Journal of the American Medical Association
  22. Outshoorn UM, Ferber A. Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: a retrospective cohort study. Am J Hematol. 2006 Dec;81(12):895-900. PubMed
  23. George JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004; 41: 60-7. PubMed
  24. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998; 13: 16-9. PubMed
  25. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45: 139-59. PubMed
  26. Vesely SK, Li X, McMinn JR, Terrell DR, George JN. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2004; 44: 1149-58. PubMed
Annonse
Annonse